Daiichi Sankyo Co., Ltd.
Daiichi Sankyo Co., Ltd. (Japan) holds 3 active US FDA Type II Drug Master Files and 29 inactive, has DMF or CEP filings on record for 10 active ingredients and is linked to 2 FDA-registered manufacturing sites. 2 FDA enforcement records are linked to it.
Sources: FDA Drug Master File list, EDQM certification database, FDA establishment registrations and enforcement records. How we read these records
Cite as: PharmaTek, “Daiichi Sankyo Co., Ltd.: DMF, site and FDA enforcement record”, record as of 16 Nov 2026, pharmatek.co.uk/directory/daiichi-sankyo-co-ltd
Overview
Daiichi Sankyo Co., Ltd. is a leading global pharmaceutical company headquartered in Tokyo, Japan. It focuses on the research, development, and marketing of pharmaceutical products, particularly in the field of cardiovascular diseases, oncology, and vaccines.
Core services & business areas
Therapeutic areas
Active ingredients with DMF or CEP filings
Substances for which Daiichi Sankyo Co., Ltd. holds, or has held, a US FDA Drug Master File or an EU CEP. A filing is not proof of current supply. Open any ingredient to see all its holders, CAS number and product patent dates.
API / Drug Master Files
Daiichi Sankyo Co., Ltd. holds 3 active (32 total) FDA Type II Drug Master Files. A Type II DMF is filed with the FDA to support an active ingredient in drug applications; an active filing can be referenced but is not proof of current supply, and inactive filings are historical.
- MAAA-1162A (COMMERCIAL)Active2019-07-31
- MAAA-1162AActive2015-12-09
- SUN11031 (HUMAN GHRELIN) DRUG SUBSTANCEActive2005-06-30
- DS-1594B DRUG PRODUCTInactive2020-11-20
- DS-1594B DRUG SUBSTANCEInactive2020-11-20
- SUN13837 DRUG SUBSTANCEInactive2009-01-09
- SUN13834 DRUG SUBSTANCEInactive2006-08-09
- BENICAR HCTR (OLMESARTAN MEDOXOMIL HYDROCHLOROTHIAZIDE) TABLETSInactive2006-07-25
- DZ-697B DRUG SUBSTANCEInactive2005-10-24
- BENICAR(TM) TABLETS 5 MG, 20 MG AND 40 MGInactive2004-09-14
- DW-908E DRUG SUBSTANCEInactive2004-07-06
- CS-088 DRUG SUBSTANCEInactive2004-06-14
- CS-023 DRUG SUBSTANCEInactive2004-03-12
- DU-176B DRUG SUBSTANCEInactive2004-02-13
- DX-619 DRUG SUBSTANCEInactive2003-07-28
- CS-917 DRUG SUBSTANCEInactive2003-04-28
- CS-917 DRUG PRODUCTInactive2003-04-22
- CS-758 DRUG SUBSTANCEInactive2002-03-20
- CS-758 DRUG PRODUCTInactive2002-03-19
- DATICHI PHARMACEUTICAL CO LTD DU-6859AInactive2001-12-20
- OLMESARTAN MEDOXOMIL DRUG SUBSTANCEInactive2000-07-14
- CS-011 DRUG PRODUCTInactive1999-07-29
- LEVOFLOXACIN DRUG SUBSTANCEInactive1993-02-26
- PRODUCTION TECHNOLOGY RESEARCH LABS., EDOGAWA-KU, TOKYO, JAPANInactive1989-04-28
- PRAVASTATIN SODIUM DRUG SUBSTANCEInactive1988-07-11
- MALOTILATE 200 MG TABLETSInactive1984-05-03
- DL 8280 MEFOXACIN A & PLACEBO TABSInactive1984-01-11
- MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN SHIZUOKA JAPAN.Inactive1983-12-09
- CETRAXATE HCl CAPSULESInactive1982-02-05
- CETRAXATE HYDROCHLORIDEInactive1982-02-05
- TRANEXAMIC ACIDInactive1980-07-10
- EPIRIZOLE (MEBRON)Inactive1976-06-15
Registered manufacturing sites (2)
Physical sites registered with the US FDA and resolved to Daiichi Sankyo Co., Ltd., with any EU/UK GMP documents matched to each site. Headquarters and manufacturing locations can differ.
FDA compliance signals
2 FDA enforcement records linked to this company.
- 4832023-12-22
Absence of Written Procedures
- 4832023-12-22
Investigations of discrepancies, failures
Is this Daiichi Sankyo Co., Ltd.?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.
Need suppliers found and checked?
The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.